类风湿关节炎治疗药物研究进展  

Advances of Pharmaceuticals against rheumatoid arthritis

作　　者：施安国[1] 

机构地区：[1]上海第二医科大学附属仁济医院临床药学实验室,上海200001

出　　处：《中国新药杂志》2006年第2期92-95,共4页Chinese Journal of New Drugs

摘　　要：类风湿关节炎是慢性自体免疫性疾病,临床用TNF-α阻滞剂、白介素-1受体阻滞剂和嘧啶合成抑制剂等药物治疗取得较好的疗效。论述了一些近年来治疗类风湿关节炎的新药,这些药物在短期和中期治疗中较为安全和有效,但长期治疗的疗效和毒性仍有待于进一步研究。Rheumatoid arthritis is a chronic inflammatory autoimmune disease. Recent advances have led to the successful use of therapies that target TNF-α, interleukin-1 and inhibition of pyrimidine synthesis. This presentation discussed several new drugs used in the treatment of rheumatoid arthritis. Although these drugs appear to be relatively safe and effective in the short-to-intermediate term, their long-term efficacy and toxicity remain to be verified in the treatment of rheumatoid arthritis.

关 键 词：类风湿关节炎 来氟米特 依那西普 英利昔单抗 ADALIMUMAB ANAKINRA 

分 类 号：R971.1[医药卫生—药品] R684.3[医药卫生—药学]